Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$5.77 - $9.82 $14.3 Million - $24.3 Million
-2,474,183 Reduced 91.13%
240,949 $1.53 Million
Q1 2024

May 15, 2024

BUY
$8.71 - $14.65 $10.2 Million - $17.1 Million
1,169,043 Added 75.61%
2,715,132 $25.2 Million
Q4 2023

Feb 14, 2024

SELL
$7.89 - $13.14 $10.9 Million - $18.2 Million
-1,383,814 Reduced 47.23%
1,546,089 $19.7 Million
Q3 2023

Nov 14, 2023

SELL
$9.88 - $14.0 $3.91 Million - $5.55 Million
-396,162 Reduced 11.91%
2,929,903 $30.3 Million
Q2 2023

Aug 14, 2023

BUY
$10.78 - $13.65 $2.62 Million - $3.31 Million
242,815 Added 7.88%
3,326,065 $43.6 Million
Q1 2023

May 15, 2023

BUY
$7.49 - $12.54 $9.89 Million - $16.6 Million
1,319,892 Added 74.85%
3,083,250 $34.5 Million
Q4 2022

Feb 14, 2023

BUY
$4.92 - $17.35 $6.08 Million - $21.5 Million
1,236,561 Added 234.73%
1,763,358 $14.9 Million
Q3 2022

Nov 14, 2022

BUY
$15.35 - $23.99 $2.04 Million - $3.2 Million
133,197 Added 33.84%
526,797 $8.78 Million
Q2 2022

Aug 15, 2022

BUY
$14.0 - $27.95 $4.54 Million - $9.06 Million
324,200 Added 467.15%
393,600 $5.79 Million
Q1 2022

May 16, 2022

SELL
$21.13 - $35.65 $5.25 Million - $8.86 Million
-248,507 Reduced 78.17%
69,400 $1.72 Million
Q4 2021

Feb 14, 2022

BUY
$29.72 - $45.1 $1.98 Million - $3.01 Million
66,707 Added 26.56%
317,907 $10.2 Million
Q3 2021

Nov 15, 2021

SELL
$35.98 - $44.48 $14.7 Million - $18.2 Million
-409,601 Reduced 61.99%
251,200 $9.04 Million
Q2 2021

Aug 16, 2021

BUY
$37.61 - $48.0 $12.6 Million - $16.1 Million
334,488 Added 102.51%
660,801 $29.2 Million
Q1 2021

May 17, 2021

BUY
$44.0 - $67.54 $10.8 Million - $16.5 Million
244,713 Added 299.89%
326,313 $14.9 Million
Q4 2020

Feb 16, 2021

BUY
$39.31 - $69.02 $3.21 Million - $5.63 Million
81,600 New
81,600 $5.63 Million

Others Institutions Holding LUNG

About Pulmonx Corp


  • Ticker LUNG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 37,268,400
  • Market Cap $236M
  • Description
  • Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...
More about LUNG
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.